Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy

#550

Introduction: Y90-DOTATATE and Y90-DOTATOC are established treatments for patients with advanced neuroendocrine tumours. Outcomes associated with improved survival following therapy are still unclear.

Aim(s): To determine clinical, biochemical and radiological response rates to Y90 therapy and their possible association with improved survival.

Materials and methods: A retrospective case note analysis was conducted on 60 patients who had recieved Y90. Clinical response was assessed subjectively. Biochemical and radiological response were assessed using WHO and RECIST criteria, respectively. Survival curves were constructed for responders (stable/regression) v. non-responders (progression).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Gilbert T, Mckane G, Banks M, Poston G, Vora J,

Keywords: Y90 DOTATOC/DOTATATE, survival,